With over 100 years of experience in the development and manufacture of temperature controlled laboratory equipment, the preparation and preservation of samples is at the heart of everything we do. Froilabo offers a complete range of temperature controlled equipment to prepare, store and test samples. Our products are designed in France and manufactured in our modern ISO 9001 and ISO 13485 certified European production facility. Since 2009, Froilabo has been part of Techcomp Europe Ltd, a group of European companies involved in the manufacture and distribution of analytical systems, life science equipment and laboratory instruments with operations dating back to 1920. In 2023 Techcomp Europe Ltd established the Lab Products Division, uniting four of the Techcomp companies to bring you a one stop solution for your sample preparation, analysis and storage.
Fore Biotherapeutics
Fore Biotherapeutics is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for patients with cancer. Our lead candidate is plixorafenib (PLX-8394; FORE-8394), an investigational novel, selective BRAF inhibitor with activity against BRAF Class I (V600) and II (non-V600) alterations. Plixorafenib does not induce paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway, and avoids certain side effects, secondary malignancies, and some mechanisms of resistance that have been described with earlier generation BRAF inhibitors. Importantly, this also avoids the need for a second anticancer agent, such as a MEK inhibitor, to suppress paradoxical MAPK pathway activation. In a phase 1/2a multi-center, single-arm study of 113 participants with BRAF-altered solid tumors (NCT02428712), plixorafenib showed good tolerability and promising antitumor activity. Adverse events included primarily low-grade liver function test abnormalities, and the most common symptomatic adverse events were grade 1 in severity. Prolonged tumor responses and disease control were observed across various solid tumors including those with BRAF V600 mutations and BRAF fusions. In this heavily pretreated population, a preliminary analysis showed an objective response rate (ORR) of 30% was observed for participants with BRAF V600 tumors (42% ORR for those patients with no prior MAPK inhibitor therapy), with a duration of response of 17.8 months. The Forte clinical trial, a phase 2 basket study (NCT05503797) of plixorafenib for participants ≥8 years old with BRAF-altered cancers, consists of four sub-protocols: A. Participants with solid tumors and BRAF fusions who have received or are not eligible for standard of care therapy. Patients should not have received prior therapy targeting the MAPK pathway, with the exception of pediatric low-grade gliomas that have not progressed on such therapy. B. Participants with recurrent primary CNS tumors with BRAF V600 mutations who have received standard-of-care therapy and have not received prior therapy targeting the MAPK pathway. C. Participants with BRAF V600-mutated solid tumors excluding primary CNS tumors, CRC, PDAC, and more common BRAF-mutated solid tumors (non-small cell lung cancer, melanoma, and anaplastic or papillary thyroid carcinoma). D. Participants with advanced primary CNS and other solid tumors with BRAF V600 mutations who are not eligible for enrollment in sub-protocols B and C, including cutaneous melanoma, differentiated thyroid cancer, non-small cell lung cancer, and participants previously receiving therapies targeting the MAPK pathway. For more information about Fore Biotherapeutics and our Forte clinical trial, please visit us at https://Fore.Bio.
Flywheel
The Flywheel medical imaging platform empowers healthcare innovation by unifying imaging data in one end-to-end platform that automates research workflows and makes data usable for AI development and secondary analysis. Scalable by design, Flywheel offers a way to securely aggregate, annotate, curate and analyze large amounts of imaging and video data for new discoveries. Our comprehensive solution allows pharmaceutical and biotechnology companies, academic medical centers, AI developers and medical device manufacturers to realize maximum value from their imaging data assets. With greater visibility and usability of their imaging data, parties across the medical landscape can accomplish more by accelerating research timelines, facilitating decision-making and laying the groundwork for audit-ready submissions.
First Defense/ImmuCell Corp.
The best vaccine for scours isn’t a vaccine. It’s antibodies. How do we know, you ask? We’ve been working in diarrhea for 30 years. We’ve seen what doesn’t work, and what does. Our First Defense® line of antibody products gives newborn calves immediate immunity from scours pathogens E.coli, rotavirus and coronavirus. There’s no reliance on dam- or calf-level vaccines to stimulate an antibody response. One dose at birth covers them. No Needles. No Scours. No Doubt. FirstDefenseCalfHealth.com
Fire Science Nutrition
Fueling firefighters to always Stay Ready with science-backed supplements. | America’s Electrolyte. Sea Salt + Coconut Water.
FERA Diagnostics & Biologicals
FERA is founded by dairy veterinarians and is dedicated to developing innovative solutions to improve welfare, productivity and health for dairy cattle. The diagnostic line centered around AccuMast has improved mastitis culturing around the world by providing rapid, easy to use and accurate on farm testing with its innovative color changing technology. FerAppease is revolutionizing the dairy industry by decreasing the stress response of cows at freshening, dry off, weaning and other stressful times. Look to FERA for innovative animal health solutions to improve animal welfare and your bottom line.
Fedegari Technologies, Inc.
Fedegari is a global leader in providing highly customized integrated solutions for the biotechnological and pharmaceutical industries. Scientific research and technological innovation have the power to improve lives: at Fedegari, this belief drives everything we do. Our Lab Solutions are designed to support those working at the forefront of science, offering high-performance, reliable systems that simplify daily laboratory workflows while ensuring uncompromising process control. Our autoclaves and washing machines are utilized in high-performing pharmaceutical and biopharmaceutical companies, microbiology and R&D laboratories, food processing, cosmetics, agricultural and packaging industries around the world. Our American headquarter is located in the Philadelphia, PA area, and our sales and service network spans the entire USA, Canada, Mexico, and Latin America.
Fapon Biopharma
Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases and other diseases where there are unmet medical needs. We have built several drug discovery platforms, including a platform for discovering biologics based on the globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. We have also built a differentiated pipeline of multiple internationally leading drug candidates. We have established a system that covers different aspects of the drug development from drug discovery, preclinical research, CMC to regulation and early clinical development. We are committed to enabling safer, more efficacious and affordable biologics.
EYED PHARMA
EyeD Pharma is a clinical stage pharmaceutical company dedicated to improving the life of patients suffering from ophthalmic diseases with unmet medical needs such as glaucoma or dry eye. We develop innovative therapeutic solutions based on sustained release polymeric micro-implants and inserts. | Micro-Implants for the Future of Eye Care Founded in 2012, EyeD Pharma is a clinical stage pharmaceutical company dedicated to improving the life of patients suffering from ophthalmic diseases with unmet medical needs such as glaucoma or dry eye. We develop innovative therapeutic solutions based on sustained release polymeric micro-implants and inserts. Our leading clinical-stage product candidate is an intraocular implant allowing a sustained release of API up to 9 years that could ensure 100% patient’s compliance and could considerably reduce treatment side effects, preventing further vision loss and drastically improving the patient’s daily quality of life. To support the development of our innovative R&D pipeline, we built our own Contract and Development Manufacturing Organization (CDMO), UniD Manufacturing, gathering our strong technological expertise and IP in three unique technology platforms, in-house tailor-made equipment, and talented experts in a highly proprietary GMP approved environment. Today, our team gathers 80+ experts and managers with an average of 18 years’ pharmaceutical expertise in our environment-friendly offices and CDMO in the Science Park of Liège, Belgium.
Exelixis, Inc.
Exelixis is innovating next-generation medicines and regimens at the forefront of cancer care. We are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics.